Natera Unveils 21 Studies at ATC, Highlighting Prospera’s Role in Transplant Outcomes — Natera, Inc.

Event summary

Natera will present 21 studies at the American Transplant Congress (ATC) from June 20-24, 2026, including seven oral presentations.
Prospera test data from the PEDAL study showed that elevated dd-cfDNA levels predicted adverse outcomes in 18.2% of kidney transplant patients with non-rejection biopsy results.
ProActive study data revealed that persistently low Prospera dd-cfDNA levels significantly reduced the odds of future rejection and graft loss in kidney transplant recipients.
Natera’s presentations cover kidney, heart, lung, and multi-organ transplants, emphasizing Prospera’s role in risk assessment and long-term graft monitoring.

The big picture

Natera’s extensive presence at the ATC underscores its commitment to advancing transplant care through precision medicine. The company’s focus on dd-cfDNA analysis positions it at the forefront of non-invasive monitoring solutions, potentially reshaping how transplant outcomes are managed. The strategic emphasis on real-world clinical impact could drive broader adoption and reimbursement discussions.

What we're watching

Clinical Adoption: How the new Prospera data will influence clinical decision-making and adoption rates among transplant centers.
Competitive Positioning: Whether Natera can sustain its leadership in dd-cfDNA testing amid potential competitive pressures.
Regulatory Pathways: The pace at which regulatory bodies may incorporate Prospera test results into transplant management guidelines.